- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01272908
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)
6 juli 2017 bijgewerkt door: Hoffmann-La Roche
Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)
This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy.
All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15.
After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera.
The anticipated time on study treatment is 48 weeks.
Studie Overzicht
Studietype
Ingrijpend
Inschrijving (Werkelijk)
120
Fase
- Fase 3
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
-
Edmonton, Alberta, Canada, T5M 0H4
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 3G8
-
Vancouver, British Columbia, Canada, V5Z 3Y1
-
Victoria, British Columbia, Canada, V8V 3P9
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1M4
-
-
Newfoundland and Labrador
-
St John's, Newfoundland and Labrador, Canada, A1A 5E8
-
St John's, Newfoundland and Labrador, Canada, A1C 5B8
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 1Y2
-
Hamilton, Ontario, Canada, L8S 4J9
-
Mississauga, Ontario, Canada, L5M 2V8
-
Nepean, Ontario, Canada, K2G 6E2
-
Ottawa, Ontario, Canada, K1H 8L6
-
Ottawa, Ontario, Canada, K1S 1C2
-
Thunder Bay, Ontario, Canada, P7B 5G3
-
Toronto, Ontario, Canada, M4K 1N2
-
Toronto, Ontario, Canada, M5T 2S8
-
Toronto, Ontario, Canada, M5G 1X5
-
Windsor, Ontario, Canada, N8X 5A6
-
-
Quebec
-
Laval, Quebec, Canada, H7G 2E6
-
Montreal, Quebec, Canada, H1T 2M4
-
Montreal, Quebec, Canada, H3T 1E2
-
Montreal, Quebec, Canada, H2L 1S6
-
Montreal, Quebec, Canada, H2L 4M1
-
Quebec City, Quebec, Canada, G1V 3M7
-
Sainte-foy, Quebec, Canada, G1W 4R4
-
Sherbrooke, Quebec, Canada, J1H 5N4
-
St-eustache, Quebec, Canada, J7P 4J2
-
Trois-rivieres, Quebec, Canada, G8Z 1Y2
-
-
-
-
-
Boras, Zweden, 50182
-
Falun, Zweden, 79182
-
Goeteborg, Zweden, 41345
-
Jonkoping, Zweden, 551 85
-
Kalmar, Zweden, 39185
-
Karlskrona, Zweden, 37185
-
Lulea, Zweden, 97180
-
Malmoe, Zweden, 20502
-
Oskarstroem, Zweden, 31392
-
Skoevde, Zweden, 54185
-
Stockholm, Zweden, 18288
-
Sundsvall, Zweden, 85186
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 80 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Adult patients, 18-80 years of age
- Moderate to severe active rheumatoid arthritis
- Inadequate response to a single previous or current treatment with an anti-TNF agent
- Methotrexate for at least 12 weeks, at a stable dose over the past 4 weeks
Exclusion Criteria:
- Previous treatment with MabThera
- Use of an anti-TNF agent within past 8 weeks (4 in the case of etanercept)
- Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate
- Active infection, or history of serious or chronic infection
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Enkele arm
|
1000 mg intravenously on Days 1 and 15
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary
Tijdsspanne: Days 1, 2, 15, and 16 and Week 48 of Initial treatment period
|
Percentage of participants who reported an AE or serious AE (SAE), a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
|
Days 1, 2, 15, and 16 and Week 48 of Initial treatment period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants With Adverse Events During the Re-Treatment Period - Overall Summary
Tijdsspanne: Days 1, 2, 15, and 16 and Week 48 of Re-treatment period
|
Percentage of participants who reported an AE or SAE, a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
|
Days 1, 2, 15, and 16 and Week 48 of Re-treatment period
|
Percentage of Participants Meeting American College of Rheumatology (ACR) Response Criteria During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
ACR20/50/70, defined as ≥20 percent (%), 50%, or 70% improvement, respectively, compared to baseline in tender joint count (TJC) and swollen joint count (SJC), and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and an acute phase reactant (erythrocyte sedimentation rate [ESR] or C-Reactive Protein [CRP]).
If CRP was missing or not done, then ESR was used.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Percentage of Participants Meeting ACR Response Criteria During the Re-treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
ACR20/50/70, defined as ≥20%, 50%, or 70% improvement, respectively, compared to baseline in TJC and SJC, and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; HAQ-DI; and an acute phase reactant (ESR or CRP).
If CRP was missing or not done, then ESR was used.
|
Weeks 12 and 24 of Re-treatment period
|
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
|
Weeks 12 and 24 of Re-treatment period
|
Percentage of Participants Meeting European League Against Rheumatism (EULAR) Response Criteria During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
The EULAR response criteria were based on the assessment of disease activity using the DAS28.
The EULAR response criteria included not only change in disease activity but current disease activity.
To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity.
There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none.
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR.
The DAS28 has a continuous scale ranging from 0 to 9.4.
The level of disease activity was interpreted as low (DAS28 score less than or equal to [≤]3.2), moderate (DAS28 score greater than [>]3.2 but ≤5.1), or high (DAS28 score >5.1).
A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Percentage of Participants Meeting EULAR Response Criteria During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
The EULAR response criteria were based on the assessment of disease activity using the DAS28.
The EULAR response criteria included not only change in disease activity but current disease activity.
To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity.
There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none.
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR.
The DAS28 has a continuous scale ranging from 0 to 9.4.
The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1).
A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in DAS28 During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR.
The DAS28 has a continuous scale ranging from 0 to 9.4.
The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1).
A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in DAS28 During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
The DAS28 scoring used 4 core components: SJC, TJC, Patient Global Assessment of Disease Activity, and ESR.
The DAS28 has a continuous scale ranging from 0 to 9.4.
The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1).
A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in SJC During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in SJC During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in TJC During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in TJC During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in Physician's Global Assessment of Disease Activity During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Physician Global Assessment of Disease Activity was measured using a 100-mm visual analog scale (VAS) where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity.
The physician marked the line and the distance from the left edge was measured in mm.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in Physician's Global Assessment of Disease Activity During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
Physician Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity.
The physician marked the line and the distance from the left edge was measured in mm.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in Patient Global Assessment of Disease Activity Score During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity.
The participant was asked to marked the line and the distance from the left edge was measured in mm.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in Patient Global Assessment of Disease Activity During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance
|
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity.
The participant was asked to marked the line and the distance from the left edge was measured in mm.
|
Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance
|
Change From Baseline in Patient Global Assessment of Pain During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain.
The participant was asked to mark the line and the distance from the left edge was measured in mm.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in Patient Global Assessment of Pain During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain.
The participant was asked to mark the line and the distance from the left edge was measured in mm.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline HAQ-DI Score During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities.
Participants report amount of difficulty in performing 2-3 specific subcategory items.
Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do).
The highest component score in each of the 8 categories determined the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3).
The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability).
HAQ-DI not computed if > 2 categories were missing.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline HAQ-DI Score During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities.
Participants report amount of difficulty in performing 2-3 specific subcategory items.
Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do).
The highest component score in each of the 8 categories determines the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3).
The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability).
HAQ-DI not computed if >2 categories were missing.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in ESR During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
ESR was measured in mm/hour and was used to determine the acute phase response.
Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in ESR During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
ESR was measured in mm/hour and was used to determine the acute phase response.
Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in CRP During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response.
A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline CRP During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
CRP levels were measured in mg/L and were used to determine the acute phase response.
A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
|
Weeks 12 and 24 of Re-treatment period
|
Percentage of Participants With Disease Remission According to DAS28 in the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR.
The DAS28 has a continuous scale ranging from 0 to 9.4.
The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1).
A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Percentage of Participants With Disease Remission According to DAS28 in the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR.
The DAS28 has a continuous scale ranging from 0 to 9.4.
The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1).
A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
|
Weeks 12 and 24 of Re-treatment period
|
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score During the Initial Treatment Period
Tijdsspanne: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale.
The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue.
Score changes of 4 points or more were considered clinically meaningful.
The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
|
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
|
Change From Baseline in FACIT-F Total Score During the Re-Treatment Period
Tijdsspanne: Weeks 12 and 24 of Re-treatment period
|
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale.
The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue.
Score changes of 4 points or more were considered clinically meaningful.
The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
|
Weeks 12 and 24 of Re-treatment period
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
18 juli 2006
Primaire voltooiing (Werkelijk)
12 maart 2009
Studie voltooiing (Werkelijk)
12 maart 2009
Studieregistratiedata
Eerst ingediend
7 januari 2011
Eerst ingediend dat voldeed aan de QC-criteria
7 januari 2011
Eerst geplaatst (Schatting)
10 januari 2011
Updates van studierecords
Laatste update geplaatst (Werkelijk)
15 augustus 2017
Laatste update ingediend die voldeed aan QC-criteria
6 juli 2017
Laatst geverifieerd
1 juni 2017
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Auto-immuunziekten
- Gewrichtsziekten
- Musculoskeletale aandoeningen
- Reumatische aandoeningen
- Bindweefselziekten
- Artritis
- Artritis, reumatoïde
- Fysiologische effecten van medicijnen
- Antireumatische middelen
- Antineoplastische middelen
- Immunologische factoren
- Antineoplastische middelen, immunologisch
- Rituximab
Andere studie-ID-nummers
- ML20381
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Reumatoïde artritis
-
wangxiaodongVoltooid
-
Second Affiliated Hospital, School of Medicine,...VoltooidSeptische arthritisChina
-
Rennes University HospitalVoltooid
-
Assiut UniversityNog niet aan het wervenSeptische arthritis
-
Assiut UniversityNog niet aan het werven
-
Assistance Publique - Hôpitaux de ParisWerving
-
Khoo Teck Puat HospitalOnbekend
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang...Werving
-
Texas Tech University Health Sciences Center, El...Beëindigd
-
Nantes University HospitalVoltooidSeptische arthritisFrankrijk
Klinische onderzoeken op rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendEBV-gerelateerde post-transplantatie lymfoproliferatieve stoornis | Monomorfe post-transplantatie lymfoproliferatieve stoornis | Polymorfe post-transplantatie lymfoproliferatieve stoornis | Terugkerende monomorfe lymfoproliferatieve stoornis na transplantatie | Terugkerende polymorfe lymfoproliferatieve... en andere voorwaardenVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingAnn Arbor stadium I graad 1 folliculair lymfoom | Ann Arbor stadium I graad 2 folliculair lymfoom | Ann Arbor stadium II graad 1 folliculair lymfoom | Ann Arbor stadium II graad 2 folliculair lymfoomVerenigde Staten
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Actief, niet wervendRecidiverend graad 1 folliculair lymfoom | Recidiverend graad 2 folliculair lymfoom | Recidiverend mantelcellymfoom | Recidiverend marginale zone-lymfoom | Refractair B-cel non-Hodgkin-lymfoom | Terugkerend klein lymfocytisch lymfoom | Recidiverend B-cel non-Hodgkin-lymfoom | Recidiverend graad... en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)VoltooidAnn Arbor stadium III graad 1 folliculair lymfoom | Ann Arbor stadium III graad 2 folliculair lymfoom | Ann Arbor stadium IV graad 1 folliculair lymfoom | Ann Arbor stadium IV graad 2 folliculair lymfoom | Ann Arbor stadium II graad 3 aaneengesloten folliculair lymfoom | Ann Arbor stadium... en andere voorwaardenVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Actief, niet wervendTerugkerend klein lymfocytisch lymfoom | Prolymfatische Leukemie | Terugkerende chronische lymfatische leukemieVerenigde Staten
-
Mabion SAParexelIngetrokken
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingChronische lymfatische leukemie/klein lymfatisch lymfoomVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendRecidiverend mantelcellymfoom | Refractair B-cel non-Hodgkin-lymfoom | Recidiverend B-cel non-Hodgkin-lymfoom | Refractair mantelcellymfoomVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendStadium I chronische lymfatische leukemie | Stadium II chronische lymfatische leukemie | Stadium III chronische lymfatische leukemie | Stadium IV chronische lymfatische leukemieVerenigde Staten, Canada
-
National Cancer Institute (NCI)Celgene CorporationActief, niet wervendAnn Arbor stadium III graad 1 folliculair lymfoom | Ann Arbor stadium III graad 2 folliculair lymfoom | Ann Arbor stadium IV graad 1 folliculair lymfoom | Ann Arbor stadium IV graad 2 folliculair lymfoom | Ann Arbor stadium II graad 3 aaneengesloten folliculair lymfoom | Ann Arbor stadium... en andere voorwaardenVerenigde Staten